Hjem › Kreft i gallesystemet › Ohio
Kliniske studier for Kreft i gallesystemet i Ohio
10 studier for Kreft i gallesystemet søker deltakere på steder i Ohio.
Byer i Ohio
Offisiell studietekst (engelsk)
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Cleveland Clinic - Oncology Department, Cleveland
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT06760819A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer
- University Hospitals Cleveland Medical Center Seidman Cancer Center (Site 111), Cleveland
- James Cancer Hospital and Solove Research Institute (Site 119), Columbus
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 29. sep. 2026 · NCT07265674Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Research Site, Cincinnati
- Research Site, Columbus
RekruttererFase 2
Alder 18 til 130 · Alle kjønn · Oppdatert 23. sep. 2026 · NCT05489211Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer
- University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland
- Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center, Cleveland
RekruttererFase 2
Alder 19 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT07146646A Phase 1 Study of LNCB74 in Advanced Solid Tumors
- Cleveland Clinic Taussig Cancer Institute, Cleveland
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 21. aug. 2026 · NCT06774963Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
- Research Site, Cleveland
- Research Site, Columbus
RekruttererFase 3
Alder 18 til 99 · Alle kjønn · Oppdatert 19. aug. 2026 · NCT06467357A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- The Ohio State University Comprehensive Cancer Center, Columbus
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 11. aug. 2026 · NCT05592626D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer
- University Hospital Cleveland Medical Center, Cleveland
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 30. jul. 2026 · NCT06622057A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Nationwide Children's Hospital, Colombus
- The Ohio State University Comprehensive Cancer Center (OSUCCC) - The James Cancer Hospital and Solove Research Institute, Columbus
- Taylor Cancer Research Center, Maumee
RekruttererFase 2
Alder 8 og eldre · Alle kjønn · Oppdatert 27. jul. 2026 · NCT05503797A Study of MT-4561 in Patients With Various Advanced Solid Tumors
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center, Columbus
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 11. des. 2025 · NCT06943521Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.